CEQUA (cyclosporine) by Fosun Pharma is calcineurin inhibitors [moa]. First approved in 2018.
Drug data last refreshed 4h ago · AI intelligence enriched Yesterday
CEQUA is a calcineurin inhibitor immunosuppressant ophthalmic solution approved in 2018 for treating dry eye disease by reducing ocular inflammation. It works by inhibiting calcineurin, a key enzyme in T-cell activation, thereby suppressing the immune-mediated inflammatory cascade that drives dry eye pathology. The drug is administered topically as an eye drop.
Product is in peak lifecycle phase with solid Part D utilization (~73K claims in 2023), indicating stable commercial performance and likely mature sales infrastructure requiring maintenance-focused team investment.
Calcineurin Inhibitors
Calcineurin Inhibitor Immunosuppressant
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults
Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study
Cyclosporine In Takotsubo Syndrome
A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.
Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA
Worked on CEQUA at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CEQUA offers a stable, mature product environment with established market presence and no imminent LOE threat until 2037. Career growth will depend on driving adoption in underdiagnosed patient populations, expanding international markets, and optimizing patient access rather than pursuing breakthrough innovation.